Chronic Hand Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic hand eczema markets reached a value of US$ 12.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 26.8 Billion by 2034, exhibiting a growth rate (CAGR) of 7.1% during 2024-2034.
The chronic hand eczema market has been comprehensively analyzed in IMARC's new report titled "Chronic Hand Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic hand eczema refers to a persistent and distressing dermatological condition characterized by inflammation and irritation of the skin on the hands. It is often exacerbated by various factors, such as genetic predisposition, frequent exposure to irritants like detergents, allergens, and environmental triggers. The symptoms of this ailment can vary in intensity but commonly include redness, itching, dryness, painful cracks, and sometimes even blisters. The affected skin may become thickened and scaly and exhibit a compromised barrier function, leading to increased vulnerability to infections and discomfort in daily activities. The diagnosis of chronic hand eczema typically involves a thorough examination by a dermatologist who considers the patient's medical history, physical symptoms, and potential triggers. In some cases, patch testing might be conducted to identify specific allergens that might be contributing to the condition. Differential diagnosis is important to rule out several other similar skin conditions like psoriasis or fungal infections.
The increasing cases of exposure to irritants and allergens in the environment that can trigger an immune response are primarily driving the chronic hand eczema market. In addition to this, the inflating utilization of topical corticosteroids, emollients, and barrier creams, which provide relief by alleviating symptoms and restoring the skin's protective barrier, is also creating a positive outlook for the market. Moreover, the widespread adoption of phototherapy, involving exposure to ultraviolet light under controlled conditions to mitigate inflammation and suppress the immune responses causing the illness, is further bolstering the market growth. Apart from this, the rising application of lifestyle adjustments and meticulous skin care regimens, since they help to prevent exacerbations of the disease, thereby enhancing treatment outcomes in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of systemic therapies and biologic agents to treat patients who do not respond to topical treatments is also augmenting the market growth. These therapeutic medications work by targeting specific parts of the immune system that are linked to inflammation. Furthermore, the escalating demand for advanced interventions like gene therapies, on account of their several benefits, such as long-lasting effects, targeted cellular modifications, fewer systemic adverse reactions, etc., is expected to drive the chronic hand eczema market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic hand eczema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic hand eczema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic hand eczema market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic hand eczema market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic hand eczema market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic hand eczema marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic hand eczema market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic hand eczema market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic hand eczema market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic hand eczema across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic hand eczema by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic hand eczema by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic hand eczema across the seven major markets?
What is the size of the chronic hand eczema patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic hand eczema?
What will be the growth rate of patients across the seven major markets?
Chronic Hand Eczema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic hand eczema drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic hand eczema market?
What are the key regulatory events related to the chronic hand eczema market?
What is the structure of clinical trial landscape by status related to the chronic hand eczema market?
What is the structure of clinical trial landscape by phase related to the chronic hand eczema market?
What is the structure of clinical trial landscape by route of administration related to the chronic hand eczema market?
The chronic hand eczema market has been comprehensively analyzed in IMARC's new report titled "Chronic Hand Eczema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic hand eczema refers to a persistent and distressing dermatological condition characterized by inflammation and irritation of the skin on the hands. It is often exacerbated by various factors, such as genetic predisposition, frequent exposure to irritants like detergents, allergens, and environmental triggers. The symptoms of this ailment can vary in intensity but commonly include redness, itching, dryness, painful cracks, and sometimes even blisters. The affected skin may become thickened and scaly and exhibit a compromised barrier function, leading to increased vulnerability to infections and discomfort in daily activities. The diagnosis of chronic hand eczema typically involves a thorough examination by a dermatologist who considers the patient's medical history, physical symptoms, and potential triggers. In some cases, patch testing might be conducted to identify specific allergens that might be contributing to the condition. Differential diagnosis is important to rule out several other similar skin conditions like psoriasis or fungal infections.
The increasing cases of exposure to irritants and allergens in the environment that can trigger an immune response are primarily driving the chronic hand eczema market. In addition to this, the inflating utilization of topical corticosteroids, emollients, and barrier creams, which provide relief by alleviating symptoms and restoring the skin's protective barrier, is also creating a positive outlook for the market. Moreover, the widespread adoption of phototherapy, involving exposure to ultraviolet light under controlled conditions to mitigate inflammation and suppress the immune responses causing the illness, is further bolstering the market growth. Apart from this, the rising application of lifestyle adjustments and meticulous skin care regimens, since they help to prevent exacerbations of the disease, thereby enhancing treatment outcomes in individuals suffering from the ailment, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of systemic therapies and biologic agents to treat patients who do not respond to topical treatments is also augmenting the market growth. These therapeutic medications work by targeting specific parts of the immune system that are linked to inflammation. Furthermore, the escalating demand for advanced interventions like gene therapies, on account of their several benefits, such as long-lasting effects, targeted cellular modifications, fewer systemic adverse reactions, etc., is expected to drive the chronic hand eczema market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the chronic hand eczema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic hand eczema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic hand eczema market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic hand eczema market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic hand eczema market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic hand eczema marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic hand eczema market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic hand eczema market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic hand eczema market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic hand eczema across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic hand eczema by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic hand eczema by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic hand eczema across the seven major markets?
What is the size of the chronic hand eczema patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic hand eczema?
What will be the growth rate of patients across the seven major markets?
Chronic Hand Eczema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic hand eczema drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic hand eczema market?
What are the key regulatory events related to the chronic hand eczema market?
What is the structure of clinical trial landscape by status related to the chronic hand eczema market?
What is the structure of clinical trial landscape by phase related to the chronic hand eczema market?
What is the structure of clinical trial landscape by route of administration related to the chronic hand eczema market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC HAND ECZEMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC HAND ECZEMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC HAND ECZEMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC HAND ECZEMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC HAND ECZEMA - UNMET NEEDS
10 CHRONIC HAND ECZEMA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC HAND ECZEMA - MARKETED PRODUCTS
11.1 List of Chronic Hand Eczema Marketed Drugs Across the Top 7 Markets
11.1.1 Toctino (Alitretinoin oral) - Stiefel Laboratories
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC HAND ECZEMA - PIPELINE DRUGS
12.1 List of Chronic Hand Eczema Pipeline Drugs Across the Top 7 Markets
12.1.1 Delgocitinib - Japan Tobacco/LEO Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Gusacitinib - Asana BioSciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC HAND ECZEMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC HAND ECZEMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC HAND ECZEMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Hand Eczema - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Hand Eczema - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Hand Eczema - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Hand Eczema - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Hand Eczema - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Hand Eczema - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Hand Eczema - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Hand Eczema - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Hand Eczema - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Hand Eczema - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Hand Eczema - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Hand Eczema - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Hand Eczema - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Hand Eczema - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Hand Eczema - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Hand Eczema - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Hand Eczema - Access and Reimbursement Overview
16 CHRONIC HAND ECZEMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC HAND ECZEMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC HAND ECZEMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC HAND ECZEMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC HAND ECZEMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC HAND ECZEMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC HAND ECZEMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC HAND ECZEMA - UNMET NEEDS
10 CHRONIC HAND ECZEMA - KEY ENDPOINTS OF TREATMENT
11 CHRONIC HAND ECZEMA - MARKETED PRODUCTS
11.1 List of Chronic Hand Eczema Marketed Drugs Across the Top 7 Markets
11.1.1 Toctino (Alitretinoin oral) - Stiefel Laboratories
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 CHRONIC HAND ECZEMA - PIPELINE DRUGS
12.1 List of Chronic Hand Eczema Pipeline Drugs Across the Top 7 Markets
12.1.1 Delgocitinib - Japan Tobacco/LEO Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Gusacitinib - Asana BioSciences
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC HAND ECZEMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC HAND ECZEMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC HAND ECZEMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Hand Eczema - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Hand Eczema - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Hand Eczema - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Hand Eczema - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Hand Eczema - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Hand Eczema - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Hand Eczema - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Hand Eczema - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Hand Eczema - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Hand Eczema - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Hand Eczema - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Hand Eczema - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Hand Eczema - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Hand Eczema - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Hand Eczema - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Hand Eczema - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Hand Eczema - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Hand Eczema - Access and Reimbursement Overview
16 CHRONIC HAND ECZEMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC HAND ECZEMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC HAND ECZEMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
